

# Michele Orditura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1967160/publications.pdf>

Version: 2024-02-01

115  
papers

5,227  
citations

81900

39  
h-index

91884

69  
g-index

117  
all docs

117  
docs citations

117  
times ranked

7998  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 646.	3.7	5
2	Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 813462.	2.8	2
3	Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 708.	2.0	4
4	Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice. <i>Cancers</i> , 2022, 14, 2102.	3.7	12
5	Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 110-113.	2.5	3
6	Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 45.	3.0	20
7	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. <i>Scientific Reports</i> , 2020, 10, 18190.	3.3	16
8	PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. <i>Frontiers in Oncology</i> , 2020, 10, 782.	2.8	11
9	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020, 12, 819.	3.7	61
10	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania "Luigi Vanvitelli". <i>ESMO Open</i> , 2020, 5, e000675.	4.5	11
11	Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2814.	4.1	18
12	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020, 11, 2083-2091.	1.8	7
13	Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 867-876.	2.0	8
14	Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer. <i>Scientific Reports</i> , 2019, 9, 16131.	3.3	19
15	Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 314-323.	1.4	3
16	Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 178.	8.6	28
17	Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. <i>Cancers</i> , 2019, 11, 399.	3.7	46
18	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. <i>Frontiers in Oncology</i> , 2019, 9, 1289.	2.8	10

#	ARTICLE	IF	CITATIONS
19	PARP inhibitors in ovarian cancer. <i>Cancer Treatment Reviews</i> , 2019, 73, 1-9.	7.7	158
20	Indocyanine Green Fluorescence Imaging-Guided Surgery in Primary and Metastatic Liver Tumors. <i>Surgical Innovation</i> , 2018, 25, 62-68.	0.9	41
21	What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2659.	4.1	41
22	Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy. <i>Future Oncology</i> , 2018, 14, 2493-2505.	2.4	15
23	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , 2018, 13, 469-479.	3.6	38
24	Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. <i>Current Oncology Reports</i> , 2018, 20, 76.	4.0	72
25	Propensity score-matched comparison between complete mesocolic excision and classic right hemicolectomy for colon cancer. <i>Minerva Surgery</i> , 2018, 73, 1-12.	0.6	5
26	Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. <i>Medical Oncology</i> , 2017, 34, 186.	2.5	7
27	Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1764-1774.	1.7	49
28	Naples Prognostic Score, Based on Nutritional and Inflammatory Status, is an Independent Predictor of Long-term Outcome in Patients Undergoing Surgery for Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 1273-1284.	1.3	100
29	Pancreatic stump closure after pancreatoduodenectomy in elderly patients: a retrospective clinical study. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 35-40.	2.9	42
30	Phosphatidylinositol 3-kinase (PI3K)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 76479-76491.	1.8	24
31	Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience. <i>PLoS ONE</i> , 2017, 12, e0173619.	2.5	16
32	Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. <i>Oncotarget</i> , 2016, 7, 4265-4278.	1.8	58
33	Does Preoperative Neutrophil to Lymphocyte Ratio Predict Disease-Free Survival Rate in Colorectal Cancer Patients Undergoing Curative Surgery?. <i>Annals of Surgery</i> , 2016, 263, e80.	4.2	0
34	Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. <i>ESMO Open</i> , 2016, 1, e000038.	4.5	66
35	Pancreatic neuroendocrine tumors: Nosography, management and treatment. <i>International Journal of Surgery</i> , 2016, 28, S156-S162.	2.7	42
36	Mediastinal sarcoid-like reaction after colon adenocarcinoma resection. <i>Asian Cardiovascular and Thoracic Annals</i> , 2015, 23, 82-84.	0.5	7

#	ARTICLE	IF	CITATIONS
37	Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. <i>Surgery</i> , 2015, 157, 285-296.	1.9	49
38	Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review. <i>International Journal of Surgery</i> , 2015, 21, S10-S14.	2.7	21
39	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence. <i>Oncology Letters</i> , 2015, 9, 542-550.	1.8	18
40	Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. <i>Oncology Letters</i> , 2015, 9, 1403-1405.	1.8	4
41	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. <i>Oncology Letters</i> , 2015, 9, 1628-1632.	1.8	25
42	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2015, 16, 561-568.	10.7	141
43	Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. <i>Surgery</i> , 2015, 158, 112-120.	1.9	71
44	Reply "Modified D2 lymphadenectomy is effective in patients with node-positive gastric cancers undergoing potentially curative total gastrectomy". <i>Surgery</i> , 2015, 158, 1447-1448.	1.9	1
45	Treatment of esophagogastric junction carcinoma: An unsolved debate. <i>World Journal of Gastroenterology</i> , 2015, 21, 4427-4431.	3.3	4
46	Treatment of gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 1635.	3.3	508
47	Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma" A Pilot Study. <i>Current Oncology</i> , 2014, 21, 125-133.	2.2	13
48	Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. <i>International Journal of Colorectal Disease</i> , 2014, 29, 89-97.	2.2	107
49	MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5503-5503.	1.6	9
50	Clinical management of advanced gastric cancer: The role of new molecular drugs. <i>World Journal of Gastroenterology</i> , 2014, 20, 14537.	3.3	41
51	Incidence and prognostic significance of HER2 overexpression in gastric cancer (GC): A mono-institutional retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 160-160.	1.6	0
52	Postoperative chemoradiation FOLFOX 4-based for R1 resected gastric cancer: A retrospective mono-institutional study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 143-143.	1.6	0
53	Increased circulating levels of VEGF-C to predict outcome in resectable gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4080-4080.	1.6	0
54	Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15257-e15257.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Correlation of 12-weeks decrease of CA19.9 with overall response rate (ORR) and progression-free survival (PFS) in advanced pancreatic cancer (APC) patients (pts) treated with first-line nab-paclitaxel (Nab-P) and gemcitabine (G).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15256-e15256.	1.6	0
56	Postoperative Detection of Circulating Tumor Cells Predicts Tumor Recurrence in Colorectal Cancer Patients. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1809-1818.	1.7	45
57	Emerging VEGF-receptor inhibitors for colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 25-37.	2.4	26
58	Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines. <i>Clinical Cancer Research</i> , 2013, 19, 3508-3519.	7.0	106
59	Preoperative treatment of locally advanced esophageal carcinoma. <i>International Journal of Oncology</i> , 2013, 43, 1745-1753.	3.3	8
60	Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. <i>Oncology Reports</i> , 2013, 30, 2992-2998.	2.6	11
61	Critical appraisal of the use of regorafenib in the management of colorectal cancer. <i>Cancer Management and Research</i> , 2013, 5, 49.	1.9	5
62	Radiofrequency-Assisted Liver Resection With a Comb-Shaped Bipolar Device Versus Clamp Crushing. <i>Surgical Innovation</i> , 2012, 19, 407-414.	0.9	6
63	Combined CD133/CD44 Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer. <i>Archives of Surgery</i> , 2012, 147, 18.	2.2	68
64	Impact of Total Fundoplication on Esophageal Transit. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, e1-e5.	2.2	26
65	Current status of targeted therapies in advanced gastric cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S29-S34.	3.4	35
66	Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 949-959.	4.1	21
67	The Over-The-Scope-Clip (OTSC) System is Effective in the Treatment of Chronic Esophagojejunal Anastomotic Leakage. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1585-1589.	1.7	35
68	Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. <i>Ecological Management and Restoration</i> , 2012, 25, 130-136.	0.4	20
69	Targeting EGFR in Pancreatic Cancer Treatment. <i>Current Drug Targets</i> , 2012, 13, 802-810.	2.1	121
70	Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2011, 6, e28841.	2.5	40
71	A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. <i>British Journal of Cancer</i> , 2011, 104, 427-432.	6.4	42
72	Behavior of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Colon Cancer Patients Undergoing Surgery. <i>Journal of Clinical Immunology</i> , 2011, 31, 1095-1104.	3.8	38

#	ARTICLE	IF	CITATIONS
73	Endoscopic Intraoperative Anastomotic Testing May Avoid Early Gastrointestinal Anastomotic Complications. A Prospective Study. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 145-152.	1.7	25
74	Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. <i>BMC Cancer</i> , 2011, 11, 126.	2.6	22
75	Trastuzumab Resistance in Breast Cancer. , 2011, , 51-60.		0
76	Adjuvant Chemoradiotherapy in Patients With Stage III or IV Radically Resected Gastric Cancer. <i>Archives of Surgery</i> , 2010, 145, 233.	2.2	17
77	Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study. <i>Cancer Investigation</i> , 2010, 28, 820-827.	1.3	18
78	Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2010, 16, 4990-5001.	7.0	79
79	Perspectives in Adjuvant Therapy of Gastric Cancer. <i>Oncology</i> , 2009, 77, 38-42.	1.9	17
80	Novel investigational drugs for gastric cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 945-955.	4.1	17
81	The Lymph Node Ratio Is a Powerful Prognostic Factor of Node-Positive Colon Cancers Undergoing Potentially Curative Surgery. <i>World Journal of Surgery</i> , 2009, 33, 2704-2713.	1.6	38
82	Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis. <i>Oncology Reports</i> , 2009, 21, 1023-8.	2.6	48
83	Prognostic Biomarkers and Targeted Therapy in Gastric Cancer: Reply. <i>World Journal of Surgery</i> , 2008, 32, 1227-1229.	1.6	6
84	Complete pathological response of colorectal liver metastases after chemotherapy and bevacizumab treatment: a case report. <i>Targeted Oncology</i> , 2008, 3, 253-258.	3.6	2
85	Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients. <i>Annals of Surgical Oncology</i> , 2008, 15, 69-79.	1.5	220
86	Integrated Therapy in Localized Gastric Cancer: Targeted and Tailored Approach. <i>Annals of Surgical Oncology</i> , 2008, 15, 2983-2985.	1.5	1
87	First-Line Chemotherapy vs Bowel Tumor Resection Plus Chemotherapy for Patients With Unresectable Synchronous Colorectal Hepatic Metastases. <i>Archives of Surgery</i> , 2008, 143, 352.	2.2	114
88	Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM) Tj ETQq0 010rgBT /Owrlck 10		
89	Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 242-248.	0.3	0
90	Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. <i>World Journal of Surgical Oncology</i> , 2007, 5, 42.	1.9	11

#	ARTICLE	IF	CITATIONS
91	Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. <i>Oncogene</i> , 2007, 26, 3654-3660.	5.9	140
92	Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery. <i>World Journal of Surgery</i> , 2007, 31, 1458-1468.	1.6	140
93	Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report. <i>Targeted Oncology</i> , 2007, 2, 253-257.	3.6	0
94	Capecitabine Plus Weekly Oxaliplatin in Gastrointestinal Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 85-89.	1.3	2
95	Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery. <i>Annals of Surgical Oncology</i> , 2006, 13, 823-835.	1.5	104
96	p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. <i>Journal of Surgical Oncology</i> , 2006, 93, 241-252.	1.7	35
97	Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. <i>Annals of Oncology</i> , 2006, 17, 1529-1532.	1.2	14
98	A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. <i>British Journal of Cancer</i> , 2005, 92, 1644-1649.	6.4	171
99	Cetuximab in the treatment of colorectal cancer. <i>Future Oncology</i> , 2005, 1, 173-181.	2.4	17
100	Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas. <i>Clinical Cancer Research</i> , 2004, 10, 3490-3499.	7.0	103
101	Prognostic Value of p27, p53, and Vascular Endothelial Growth Factor in Dukes A and B Colon Cancer Patients Undergoing Potentially Curative Surgery. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 1904-1914.	1.3	30
102	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. <i>Cancer</i> , 2004, 100, 270-278.	4.1	100
103	The role of EGFR inhibitors in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2004, 16, 130-135.	2.4	91
104	Normal Interleukin-10 Serum Level Opposed to High Serum Levels of Carbohydrate Antigen 19-9 and Cancer Antigens 125 and 50 in a Case of True Splenic Cyst. <i>Archives of Medical Research</i> , 2003, 34, 145-148.	3.3	12
105	Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 501-514.	2.4	27
106	A True Splenic Cyst Producing Carbohydrate Antigen 19-9 and Cancer Antigens 50 and 125, but Not Interleukin 10. <i>Digestive Surgery</i> , 2003, 20, 71-74.	1.2	7
107	Elevated Serum Levels of Interleukin-8 in Advanced Non-Small Cell Lung Cancer Patients: Relationship with Prognosis. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 1129-1135.	1.2	70
108	Preoperative Chemoradiotherapy for Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus. <i>Chest</i> , 2002, 122, 1302-1308.	0.8	52

#	ARTICLE	IF	CITATIONS
109	Prognostic Significance of Circulating IL-10 and IL-6 Serum Levels in Colon Cancer Patients Undergoing Surgery. <i>Clinical Immunology</i> , 2002, 102, 169-178.	3.2	196
110	Circulating Levels of Interleukin-10 and Interleukin-6 in Gastric and Colon Cancer Patients Before and After Surgery: Relationship with Radicality and Outcome. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 473-482.	1.2	60
111	Interleukin-6 Serum Level Correlates with Survival in Advanced Gastrointestinal Cancer Patients but Is Not an Independent Prognostic Indicator. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 45-52.	1.2	76
112	Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 530-536.	4.2	51
113	Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients. <i>Chest</i> , 2000, 117, 365-373.	0.8	139
114	Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. , 1999, 86, 1936-1943.		75
115	Adult Wilms' tumor. , 1997, 80, 1961-1965.		27